Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Alexandria Real Estate Equities, Inc. (ARE) — XLRE Real Estate · S&P 500 Profile |亞歷山德里亞房地產公司介紹

real-estateS&P500xlre
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Alexandria Real Estate Equities, Inc. (ARE) — Business, History & S&P 500 Profile |亞歷山德里亞房地產公司介紹

Alexandria Real Estate Equities company profile · life science Megacampus REIT · history · financial snapshot · S&P 500 rank #500 · 亞歷山德里亞房地產公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 5, 2026 (Slickcharts)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$7.92B
Nov 5, 2026 · Slickcharts
S&P 500 WEIGHT
0.01%
Rank #500 · Nov 5, 2026 (Slickcharts)
FY2025 TOTAL REVENUES
$3.03B
−2.9% YoY · Income from rentals $2.95B
FY2025 FFO, AS ADJUSTED
$1.53B
Per diluted share $9.01 · GAAP net loss $(1.44)B

SNAPSHOT

TickerARE (NYSE)
CompanyAlexandria Real Estate Equities, Inc.
GICS sector / industryReal Estate / Health Care REITs
S&P 500 rank (by weight)#500 · 0.01% (Nov 5, 2026)
Sector rank (by S&P 500 weight)#30 in Real Estate (Nov 5, 2026)
HeadquartersPasadena, California
Founded1994, founded by Joel S. Marcus and Jerry M. Sudarsky
CEOPeter M. Moglia (CEO & chief investment officer)
Employees514 employees (FY2025 10-K)
Market cap$7.92B (Nov 5, 2026)
SEC filingsEDGAR — CIK 0001035443

WHAT IT DOES

Alexandria Real Estate Equities, Inc. is a real estate investment trust (REIT) that pioneered life science real estate. It owns, operates and develops collaborative Megacampus ecosystems — laboratory and office campuses — in AAA life science and advanced-technology cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City, leased to life science, agtech, technology and digital-health tenants.

FY2025 total revenues were $3.03B, down 2.9% year on year, of which income from rentals was $2.95B (including tenant recoveries of $760.3M). GAAP results were dominated by impairments: net loss attributable to common stockholders was $1.44B, or $8.44 per diluted share, against net income of $309.6M, or $1.80, in 2024. Funds from operations (FFO), as adjusted, were $1.53B, or $9.01 per diluted share, against $1.63B, or $9.47, in 2024 — the REIT headline measure, because depreciation and impairments obscure property cash flow in GAAP earnings.

Alexandria is a single-segment landlord: value is created by leasing, developing and redeveloping campus space, recycling capital through dispositions and partial-interest sales ($1.47B completed in Q4 2025 alone), and holding occupancy. At December 31, 2025, occupancy of operating properties in North America was 90.9%, 78% of annual rental revenue in effect came from the Megacampus platform, and 97% of leases contained annual rent escalations.

REVENUE — FY2025

SegmentRevenuesShareYoY
Income from rentals$2.95B97.3%—
Other revenues$81.4M2.7%—
The table disaggregates total revenues into income from rentals and other revenues, as disclosed for FY2025 (10-K basis); the two rows sum to total revenues of $3.03B. Tenant recoveries of $760.3M are included within income from rentals. FY2024 total revenues were $3.12B, so total revenues fell 2.9% (computed); a like-for-like split of the FY2024 comparative is not stated here. Alexandria reports a single operating segment.

HISTORY

YearMilestone
1994Alexandria is founded in 1994 by Joel S. Marcus and Jerry M. Sudarsky, pioneering dedicated life science real estate.
1997Alexandria completes its initial public offering on the New York Stock Exchange.
2024Peter M. Moglia serves as chief executive officer and chief investment officer, with founder Joel S. Marcus as executive chairman.

COMPETITIVE POSITION

  • The preeminent life science landlord, competing with Healthpeak Properties, BXP’s life science assets and private developers; its edge is cluster dominance — Megacampus ecosystems in the top innovation locations, long leases to investment-grade and large-cap tenants (53% of annual rental revenue), and development capability.
  • FFO, not GAAP earnings, is the scoreboard: FY2025 FFO as adjusted of $9.01 per diluted share fell 4.9% while the GAAP loss was driven by roughly $1.45B of Q4 impairments alone, a valuation reset rather than a rent-collection failure (Q4 tenant rents collected were 99.9%).
  • The cycle is the constraint: biotech funding and lab-space supply set leasing spreads — renewal and re-leasing rental rates fell 9.9% in Q4 2025 even as full-year rates rose 7.0%.

FINANCIAL SNAPSHOT — FY2025

Total revenues$3.03B
Income from rentals$2.95B
FFO, as adjusted$1.53B
FFO per diluted share, as adjusted$9.01
Net loss attributable to common stockholders$(1.44)B
Diluted EPS$(8.44)
FY2025 ended Dec 31, 2025; Form 10-K for FY2025. Prior-year figures: total revenues $3.12B, FFO as adjusted $1.63B ($9.47 per diluted share), net income attributable to common stockholders $309.6M ($1.80 per diluted share), so total revenues fell 2.9% and FFO per share fell 4.9% (as reported). Occupancy of North American operating properties was 90.9% at Dec 31, 2025. The Q4 2025 dividend was cut 45% to $0.72 per share, a 33% FFO payout ratio.

KEY RISKS

  • Impairment and valuation risk: FY2025 GAAP losses were driven by asset impairments (about $1.45B in Q4 alone); further lab-space repricing would cut NAV and earnings again.
  • Leasing-cycle risk: occupancy fell to 90.9% and Q4 renewal rates fell 9.9%; a weak biotech funding cycle slows absorption of development and vacant space.
  • Tenant and cluster concentration: revenues depend on life science tenants in a handful of clusters; a large tenant failure or cluster downturn concentrates quickly.
  • Capital-recycling risk: the plan leans on dispositions and partial-interest sales at acceptable prices to fund development and deleveraging; weak transaction markets would slow it.

WHY IT MATTERS FOR THE S&P 500

Alexandria is the S&P 500’s life science real estate bellwether: its occupancy, leasing spreads and FFO read as a gauge of biotech funding, lab demand and innovation-cluster health. At rank #500 by weight (0.01%) — Real Estate #30 — it is the smallest index member by weight in this batch, representing the specialised health-care REIT inside the real estate sector.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price, market cap — Nov 5, 2026 crawl, single source)
FinancialsForm 10-K for FY2025 (year ended Dec 31, 2025)
Sector classificationGICS via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

Alexandria

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號ARE(NYSE)
公司Alexandria Real Estate Equities, Inc.
GICS 板塊/行業房地產/Health Care REITs
標普500排名(按權重)第500名 · 0.01%(2026 年 11 月 5 日)
板塊內排名(按標普500權重)房地產第30名(2026 年 11 月 5 日)
總部加州帕薩迪納
成立1994年,由 Joel S. Marcus 及 Jerry M. Sudarsky 創立
行政總裁Peter M. Moglia(行政總裁兼首席投資總監)
員工514 名員工(FY2025 10-K)
市值$7.92B(2026 年 11 月 5 日)
SEC 文件EDGAR — CIK 0001035443

業務概覽

亞歷山德里亞房地產是一家房地產投資信託基金(REIT),是生命科學房地產的先驅。它在 AAA 級生命科學及先進科技集群地點擁有、營運及開發協作式 Megacampus 生態系統——實驗室及辦公室園區——包括大波士頓、三藩市灣區、聖地牙哥、西雅圖、馬里蘭、研究三角及紐約市,出租予生命科學、農業科技、科技及數碼健康租戶。

FY2025 總收入為30.3億美元,同比下跌2.9%,其中租金收入為29.5億美元(包括租戶補償7.603億美元)。GAAP 業績受減值主導:歸屬於普通股股東的淨虧損為14.4億美元,攤薄每股虧損8.44美元,而2024年為淨利潤3.096億美元,攤薄每股收益1.80美元。經調整營運資金(FFO)為15.3億美元,攤薄每股9.01美元,而2024年為16.3億美元,攤薄每股9.47美元——這是 REIT 的 headline 指標,因為折舊及減值會掩蓋 GAAP 盈利中的物業現金流。

亞歷山德里亞是單一板塊的業主:價值來自出租、開發及再開發園區空間,透過出售及出售部分權益(僅2025年第四季已完成14.7億美元)循環資本,以及維持出租率。截至2025年12月31日,北美營運物業出租率為90.9%,生效年租金收入的78%來自 Megacampus 平台,97%的租約載有年度租金上調條款。

收入 — FY2025

板塊收入佔比同比
租金收入29.5億美元97.3%—
其他收入8,140萬美元2.7%—
本表將總收入拆分為租金收入及其他收入,按 FY2025 披露(10-K 基礎);兩行合計等於總收入30.3億美元。租戶補償7.603億美元計入租金收入之內。FY2024 總收入為31.2億美元,故總收入下跌2.9%(推算);本表不列出 FY2024 比較數字的同類拆分。亞歷山德里亞報告單一營運板塊。

歷史沿革

年份里程碑
1994年亞歷山德里亞於1994年由 Joel S. Marcus 及 Jerry M. Sudarsky 創立,開創專門的生命科學房地產領域。
1997年亞歷山德里亞於紐約證券交易所完成首次公開發售。
2024年Peter M. Moglia 出任行政總裁兼首席投資總監,創辦人 Joel S. Marcus 擔任執行主席。

競爭地位

  • 首屈一指的生命科學業主,與 Healthpeak Properties、BXP 的生命科學資產及私人開發商競爭;其優勢在於集群主導地位——在頂級創新地點的 Megacampus 生態系統、向投資級及大型租戶的長期租約(佔年租金收入53%),以及開發能力。
  • FFO 而非 GAAP 盈利是計分板:FY2025 經調整 FFO 為攤薄每股9.01美元,下跌4.9%,而 GAAP 虧損主要由僅第四季約14.5億美元的減值帶動,屬估值重置而非收租失敗(第四季租戶租金收取率為99.9%)。
  • 週期是制約因素:生物科技融資及實驗室空間供應決定租賃差價——2025年第四季續租及再出租的租金下跌9.9%,儘管全年租金上升7.0%。

財務快照 — FY2025

總收入30.3億美元
租金收入29.5億美元
經調整 FFO15.3億美元
攤薄每股經調整 FFO9.01美元
歸屬於普通股股東的淨虧損(14.4)億美元
攤薄每股收益(8.44)美元
FY2025 截至2025年12月31日;10-K 為 FY2025 年度。上年數字:總收入31.2億美元,經調整 FFO 16.3億美元(攤薄每股9.47美元),歸屬於普通股股東的淨利潤3.096億美元(攤薄每股1.80美元),故總收入下跌2.9%,每股 FFO 按報告下跌4.9%。截至2025年12月31日,北美營運物業出租率為90.9%。2025年第四季股息削減45%至每股0.72美元,FFO 派息比率為33%。

主要風險

  • 減值及估值風險:FY2025 的 GAAP 虧損由資產減值帶動(僅第四季約14.5億美元);實驗室空間若進一步重估,將再次削減資產淨值及盈利。
  • 租賃週期風險:出租率跌至90.9%,第四季續租租金下跌9.9%;生物科技融資週期轉弱會減慢開發及空置空間的吸納。
  • 租戶及集群集中風險:收入依賴少數集群的生命科學租戶;大型租戶倒閉或集群下滑會迅速集中反映。
  • 資本循環風險:計劃依賴以可接受價格出售及出售部分權益,以支持開發及去槓桿;交易市場疲弱將令計劃放緩。

對標普500的重要性

亞歷山德里亞是標普500中生命科學房地產的風向標:其出租率、租賃差價及 FFO,可反映生物科技融資、實驗室需求及創新集群的景氣。按權重排名第500位(0.01%)——房地產第30名——它是本批中按權重最小的指數成員,代表房地產板塊內的專門醫療 REIT。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格、市值——2026 年 11 月 5 日抓取,單一來源)
財務FY2025 10-K(截至2025年12月31日的年度)
板塊分類GICS,據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

Alexandria

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · ARE
Data as of Nov 5, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · The Mosaic Company (MOS) — XLB Materials · S&P 500 Profile |美盛公司介紹Next · MGM Resorts International (MGM) — XLY Consumer Discretionary · S&P 500 Profile |美高梅度假村公司介紹

Entered 2026-11-04 17:09 · updated 2026-11-14 21:33 · rev 5